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Abbreviations:  
BMI, body-mass index 
BPE, benign pleural effusion 
HH, hepatic hydrothorax 
IPC, indwelling pleural catheter 
MELD, model for end-stage liver disease 
NASH, non-alcoholic steatohepatitis 
SBE, spontaneous bacterial empyema 
TIPS, transjugular intrahepatic portosystemic shunt 
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ABSTRACT 
Background: Treatment of hepatic hydrothorax (HH) generally involves sodium 
restriction, diuretics, and serial thoracentesis.  In more advanced cases, transjugular 
intrahepatic portosystemic shunt (TIPS) and liver transplantation may be required.  In the 
past, indwelling tube drainage has been avoided due to concerns about high complication 
rates and overall poor outcomes.  Recently, indwelling pleural catheters (IPCs) have been 
proposed as a novel treatment option for HH.   
Methods: We retrospectively reviewed patients who had undergone IPC placement for 
HH over a 10-year period at a large liver transplant referral center.  We tracked 
outcomes, including complication rates and liver transplantation, as well as biomarkers of 
nutritional status. 
Results: Sixty-two patients underwent IPC placement between 2007 and 2017, with 33 
(53%) of IPCs placed as a bridge to liver transplant.  Complications were seen in 22 
(36%) of patients, with empyema being the most common in 10 (16.1%).  10 patients 
evaluated for liver transplant were successfully transplanted after IPC placement.  There 
were statistically significant decreases in both body mass index and serum albumin levels 
after IPC placement.   
Conclusions: IPCs represent a potential treatment for refractory hepatic hydrothorax and 
should be used with caution in patients eligible for liver transplantation.  Ideally, IPC use 
for these patients would be evaluated by a multidisciplinary team.  IPC use may lead to 
small decreases in BMI and serum albumin levels in patients over time.   
 
Keywords: Hepatic hydrothorax; indwelling pleural catheter  
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Introduction 
Hepatic hydrothorax (HH) is a pleural effusion in a patient with portal 
hypertension without a primary cardiac, pulmonary, or pleural disease1.  It is an 
uncommon complication of portal hypertension, occurring in approximately 5-10% of 
patients with cirrhosis1,2,3,4.  Development of hydrothorax carries a poor prognosis, with a 
median survival of 8.6 months5. 
Management of HH centers on salt restriction, diuretics, and serial thoracentesis2.   
Transjugular intrahepatic portosystemic shunt (TIPS) can be an effective treatment for 
those who fail medical management, with success rates as high as 80% 6,7. Unfortunately, 
many patients with HH have contraindications to TIPS (i.e. hepatic encephalopathy or 
hyperbilirubinemia).  Transplant is the only other treatment shown to be effective for 
patients who fail medical management8. 
Historically, tube thoracostomy has been strongly discouraged in HH due to 
concerns about complications, including renal failure, infection, electrolyte depletion, and 
protein loss9,10,11.  However, newer indwelling tunneled pleural catheters (IPCs) have 
been proposed as a novel treatment approach for the patient with refractory hydrothorax.  
The tunneled nature of these catheters theoretically ameliorates the risk of infection. 
These pleural catheters are widely accepted as an option for symptomatic management of 
malignant pleural effusions12,13, with increasing attention to their potential therapeutic 
applications in non-malignant effusions14,15.  Some centers have begun utilizing IPCs for 
treatment of HH16,17.  Recently, a pilot study with 24 transplant-eligible patients 
demonstrated feasibility of this approach18.  
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The purpose of this study was to assess outcomes and complication rates of 
patients who underwent IPC placement for HH at a large tertiary referral center for 
patients with advanced liver disease.  Our study, which includes a significant portion of 
patients who were eligible for liver transplantation, represents the largest series of such 
patients described in the literature to date. 
 
Materials and Methods 
A single-center, retrospective analysis was performed on all patients from 2007 to 
2017 with a diagnosis of cirrhosis who underwent placement of an IPC.  Data was 
extracted from the electronic medical record system (Cerner Corporation, Kansas City, 
MO) using search terms ‘cirrhosis’ and ‘IR Insert Tunneled Cath Pleural’ in order to 
capture those IPCs placed by the interventional radiology service at our institution.  A 
subsequent query using the terms ‘cirrhosis’ and ‘pleural catheter’ was performed under 
the endoscopy schedule in the same electronic records system to identify those patients 
who underwent IPC placement by the pulmonary service.  At our institution, it is standard 
that interventional radiology places either the Aspira™ (C.R. Bard, Murray Hill, NJ) or 
Pleurx™ (BD, Sydney, Australia) catheters, while the pulmonary service exclusively 
places Pleurx™ (BD, Sydney, Australia) catheters.   
Inclusion criteria included age greater than or equal to 18 years, diagnosis of 
cirrhosis and hepatic hydrothorax, and IPC placement for management of recurrent 
effusion.  Exclusion criteria included patients with a pleural effusion due to a condition 
other than hepatic hydrothorax or those who had a diagnosis of empyema prior to IPC 
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placement.  A diagnosis of hepatic hydrothorax was confirmed by the presence of a 
recurrent effusion in the setting of cirrhosis for which alternate etiologies had been 
excluded.  Prior pleural fluid studies were examined when possible.  The Institutional 
Review Board (IRB) of Indiana University School of Medicine approved the study 
protocol (protocol number 1701955275).  
  
Procedure 
Patients underwent IPC placement per standard practice of the interventional 
radiology service or the pulmonary service.  Both the Pleurx™ (BD, Sydney, Australia) 
and Aspira™ (C.R. Bard, Murray Hill, NJ) catheters are 15.5 Fr silicone tubes designed 
for placement using local anesthetic and light to moderate sedation19.  Procedures were 
performed during either inpatient or outpatient encounters.  All procedures were 
performed in operating rooms (ORs), using standard sterile procedure.  Peri-procedural 
antibiotics were administered in some cases.  Patients were provided the appropriate 
drainage equipment per standard practice and follow-up was dictated by their clinical 
course.  
 
Data Collection 
Data collected at the time of IPC placement included age, gender, body mass 
index (BMI), etiology of cirrhosis, serum bilirubin, creatinine, international normalized 
ratio (INR), sodium, and albumin levels.  In cases where laboratory and BMI data were 
not available on the day of IPC placement, values within 14 days prior to the procedure 
were accepted.  Additional baseline data points included prior therapeutic interventions 
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for hydrothorax (including salt restriction, diuretics, prior thoracentesis, prior TIPS, 
pleurodesis, or octreotide).  Date, laterality, type of IPC, reason for IPC placement, and 
liver transplant status were also collected at baseline.  Patients who were listed for 
transplant, or actively under evaluation for listing were classified as ‘bridge to 
transplant,’ while those who were definitively not transplant candidates, including those 
enrolling in comfort-based care, were classified as ‘palliative.’  There were some patients 
for whom it was not clear from available documentation whether the IPC was placed with 
palliative intent or as a bridge to transplant; these patients were classified as ‘unclear.’ 
Follow-up data included presence of complications, categorized as empyema, 
catheter site infection, catheter dislodgement, pneumothorax, catheter malfunction, 
hemothorax, or other. Catheter malfunction referred to issues connecting the IPC with the 
associated drainage system and issues with drainage due to catheter occlusion.  Empyema 
was defined as an infection of the pleural space confirmed by positive pleural fluid 
cultures or an exudative effusion with clinical signs of infection.  Pleural fluid studies in 
patients with infectious complications were collected when able.  Pleurodesis after IPC 
placement was included, defined as resolution of the effusion after IPC placement 
allowing for catheter removal based on clinician discretion without additional 
intervention.  Presence of unexpandable lung was recorded and defined as inability of the 
lung to completely expand after IPC placement despite drainage20.  Data regarding 
transplant status post-IPC, receipt of liver transplant, IPC removal, hospitalizations 
within 6 months post-IPC placement at our institution, follow-up serum albumin and 
BMI data, and death were also collected.  Follow-up albumin and BMI data were first 
collected during the initial hospitalization post-IPC placement to minimize confounding 
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from albumin infusions and additional interventions during the hospital stay.  In those 
patients who were not hospitalized within six months, the data points closest to IPC 
removal were recorded.  Death was recorded as a composite outcome that included actual 
date of death or discharge to hospice care.  No additional follow-up data was recorded 
after discharge to hospice in applicable patients.   
 
Statistical Analysis 
Data were collected from medical records and managed using REDCap electronic 
data capture tools hosted at the Indiana Clinical and Translational Sciences Institute21.  
Descriptive statistics were used to analyze demographic data.  Model for End-Stage Liver 
Disease (MELD-Na) scores were calculated from baseline laboratory values22.  Means 
and standard deviations (SD) were reported for all continuous data. Paired t-tests were 
used to compare baseline and follow-up albumin and BMI values.  The data was analyzed 
using SAS version 9.4 (SAS Institute, Cary, NC).  Statistical analysis support was 
provided by the Indiana University Department of Biostatistics.   
 
Results 
A total of 62 patients were included in the analysis.  The mean age at time of IPC 
placement was 61 years (range 35-89) (see Table 1), and 34 (55%) were male.  The most 
common etiology of cirrhosis was non-alcoholic steatohepatitis (NASH) (42%), followed 
by alcohol (32%). The mean MELD-Na score at time of IPC placement was 24 (range 
11-38).  The majority of effusions were right-sided, and the most common type of 
catheter placed was the Aspira drain used in 36 (58%) patients.  The majority of patients 
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had received prior therapy with salt restriction, diuretics, and serial thoracentesis.  Five 
patients underwent TIPS prior to IPC placement.  Twenty-one patients (34%) received 
peri-procedural antibiotics.   
Thirty-three of the 62 patients (53%) had IPCs placed as a bridge to transplant, 
while 24 patients (39%) had the catheters placed with palliative intent.  In the remaining 
5 patients, the context of IPC placement could not be discerned. Twenty-two (35%) of the 
IPCs were ultimately removed: 9 due to pleurodesis (5 in transplant group, 4 in unclear 
group), 6 after transplant, and 7 due to complications which included empyema (2), 
dislodgement (1), and others (4).  The mean time to pleurodesis was 118 days (range 15-
373).  Forty-eight of the patients died during the study period, with a mean time to death 
after IPC placement of 180 days (range 0-1258).  This included 19 (58%) patients where 
IPC was used as a bridge to transplant.  Five patients (8%) were lost to follow-up.  
   
Complications 
Catheter-related complications occurred in 22 patients (see Table 2).  The most 
serious complication was empyema, seen in 10 patients (16.1%).  In 3 of these, death was 
directly related to the empyema.  Specific details regarding patients with empyema can be 
seen Table 3.  Other notable complications include catheter dislodgement (6), 
pneumothorax (2), and cellulitis (1).  Unexpandable lung was diagnosed in 3 patients 
after IPC placement, 2 of which were successfully listed and received a liver transplant, 
with IPC removal at the time of transplant or shortly thereafter.  The third patient was 
listed after IPC placement, but suffered additional complications including infection of 
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the pleural space and died in the intensive care unit of multi-organ dysfunction syndrome 
prior to transplant.     
    
Transplant Outcomes 
Thirty-three patients were under consideration for liver transplantation at the time 
of IPC placement (see Figure 1).  Of those, 7 patients were actively listed for transplant 
when the catheter was placed.  Twelve additional patients were listed after IPC 
placement, for a total of 19 patients listed for liver transplant.  Of these, 10 went on to 
receive successful transplantation, with a mean time to transplant after IPC placement of 
87 days (range 20-175).  In 6 patients, the IPC was removed after transplant, and in 3 it 
was removed prior to transplant.  One of these 3 patients developed an empyema, 
recovered, and was successfully transplanted.  One patient died of refractory shock, with 
the IPC still in place in the days following transplant.  Of the remaining 9 patients who 
were listed, 1 was lost to follow-up, and 8 died while awaiting transplant.  Of these 8, 2 
died due to septic shock related to empyema, whereas the others died of various 
complications of end-stage liver disease that appeared unrelated to the IPC.  Of the 
original 33 patients under consideration for transplant at the time of IPC placement, 14 
were never listed for transplant.   
 
Effect on Albumin and BMI 
The mean baseline BMI was 27.8 kg/m2 (n=56; range 15.7-57.1) (see Figure 2).  
The mean follow-up BMI was 26.7 kg/m2 (n=53; range 16.0-57.1), with a mean time to 
follow-up of 32.6 days (range 1-141).  The mean difference between pre and post-IPC 
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BMI values was a decrease of 1.13 kg/m2 (n=50), which reached statistical significance 
(p=0.008).   The mean baseline serum albumin level was 3.0 g/dL (n=59; range 1.7-5.3), 
with mean follow-up level of 2.7 g/dL (n=55; range 1.2-4.2) (see Figure 3).  The mean 
time to follow-up for albumin was 29.6 days (range 1-122).  The mean difference 
between pre and post-IPC values was a decrease of 0.3 g/dL (n=53), which also reached 
statistical significance (p=0.005).   
 
Discussion 
IPCs are now accepted for the management of symptomatic malignant pleural 
effusions12,13, and their use has recently been expanded to many forms of benign pleural 
effusion (BPE)14,15.  We report the largest study to date assessing outcomes of IPCs in 
patients with medically refractory HH at a large tertiary liver transplantation center.  The 
majority of the patients included in this study had either failed prior TIPS or were not 
considered candidates for TIPS, necessitating alternate means of controlling their HH.  
Common contraindications to TIPS include prior history of hepatic encephalopathy, 
hyperbilirubinemia, pulmonary hypertension, severe congestive heart failure, and 
structural lesions of the liver that may preclude placement of the shunt22. 
Our study revealed complications in 36% of patients.  A recent review of 325 
patients with BPE who underwent IPC placement demonstrated a complication rate of 
17% in the study population15.  Notably, this review included a majority of patients with 
cardiac and renal-related pleural effusions, with only a minority of cases (12%) with liver 
disease.  Our complication rate was considerably higher.  One possible explanation for 
this finding is the natural course of patients with end-stage liver disease, including high 
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rates of infection and death5.  This theory is supported by our finding that the mean 
MELD-Na score at the time of IPC placement in our study population was 24, which 
suggests a 3-month mortality rate of approximately 20% 23. 
The most important complication of IPCs was empyema, diagnosed in 10 patients 
(16.1%).  This rate is higher than that seen thus far in patients with IPCs placed after 
solid organ transplantation (11%) and in those with hematologic malignancies 
undergoing chemotherapy (5.2%-7.7%)24,25,26.  However, this rate is almost identical to 
that seen in a recent prospective feasibility study (16.7%) assessing IP s as a bridge-to-
transplant strategy in patients with HH at a separate liver transplant referral institution18. 
This number is also comparable to a retrospective analysis of 508 cirrhotic patients with 
HH treated with thoracentesis in which the incidence of spontaneous bacterial empyema 
(SBE) was 15.9%27.  In our study, 3 (4.8%) cases of empyema necessitated IPC removal 
and in 3 (4.8%) cases the empyema precipitated septic shock and death; thus, it represents 
a serious concern in patients being considered for IPC placement. 
It should be noted that many of the pleural infections identified in this study likely 
represent spontaneous bacterial empyema, whereby bacterial infection of the pleural 
space occurs via translocation of enteric bacteria into the pleural space28.  Thus, the 
infections may not have been directly caused by the catheters themselves.  This is 
supported by the predominance of gram-negative and enteric pathogens isolated from 
pleural cultures.   Patients with hepatic hydrothorax have demonstrably lower 
complement levels and decreased opsonic activity in pleural fluid compared to patients 
with effusions of other causes, which may predispose this population to pleural space 
infections29.  Prior data in patients with IPCs for malignant pleural effusions showed 
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Staphylococcus aureus was the most common bacteria isolated from pleural cultures, and 
patients with gram-negative pathogens had worse outcomes, including death; in this 
cohort, the majority of patients were successfully treated without IPC removal30.  In 
addition, 4 of the 10 patients with pleural space infections in our study had transudative 
effusions.  Prior data has also shown traditional markers such as fluid LDH may be a less 
reliable marker of infection in patients with HH who develop SBE31.  Thus, the 
significance of transudative effusions with positive cultures in the setting of an IPC is less 
clear.  Lastly, some of the pleural fluid isolates in our study represented common skin 
flora, and we cannot rule out that in these cases that there was simply contamination 
rather than true infection.  This would lower our true infection rate to more closely align 
with other recent studies.  However, these patients were treated with antibiotics, so 
infection was assumed.   
In our study, 10 of the 33 patients (30%) who were considered eligible for 
transplant went on to successfully receive a liver transplant, which is similar to the 25% 
of patients who were ultimately transplanted in a smaller pilot study of IPC feasibility for 
medically refractory HH18.  In our study, IPCs were successfully removed in all 
transplanted patients with the exception of one patient who developed significant post-
operative complications unrelated to the IPC and ultimately died.  We did identify 2 
patients who developed empyema while they were actively listed, and both died of septic 
shock, demonstrating the risk that IPC-related complications may preclude liver 
transplantation.   
Prior studies have cited protein loss and electrolyte abnormalities as 
complications of traditional tube thoracostomy in HH10,11.  We did see statistically 
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significant decreases in both measures, although the absolute decreases were small and of 
questionable clinical significance.  Furthermore, the lack of a control group prevented us 
from assessing whether these effects truly related to the IPC or were simply 
manifestations of progressive end-stage liver disease.   
Our study has several limitations.  First, the retrospective and observational nature 
of this study means the data is subject to bias and limits the strength of our conclusions.  
All records were reviewed in detail, however only follow-up data that was available in 
our institution’s records could be obtained, thus it is possible that additional 
complications could have occurred outside of our network.  A small portion (8%) of the 
patients were ultimately lost to follow-up, including one patient who was actively listed 
for liver transplant, thus their final outcomes are unknown.  The albumin and BMI data 
may also be subject to bias, and it is possible that data may have been influenced by 
factors that were not specifically captured in the electronic medical record.  Our results 
may be subject to selection bias, and it is possible we may not have identified all patients 
who may have benefitted from an IPC.  Lastly, patients in this study were not given a 
standardized drainage protocol, which has shown benefit in patients with malignant 
pleural effusion32. 
 
Conclusions 
In conclusion, we present our single-center experience with IPC use in patients 
with medically refractory hepatic hydrothorax.  We believe that IPCs can serve as an 
effective means of palliation in patients with end-stage liver disease that are not 
transplant candidates and suffer from refractory hydrothorax.  All such patients should be 
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counseled on the potential risks of this approach, including infection.  We believe IPCs 
should be used with caution in patients who are eligible for liver transplantation.  While 
we demonstrated success with IPCs as a bridge to transplant, we also observed cases in 
which complications of the IPC actually prevented patients’ ability to undergo 
transplantation. Patients who are eligible for transplant and suffering from HH that have 
failed traditional treatment strategies would likely benefit from a multidisciplinary 
approach to care, including input from experts in the fields of Hepatology, Pulmonology, 
and Transplant Surgery.  Prospective studies would help to identify the ideal patient 
population.  Future controlled studies are also needed to better assess the effects of this 
approach with regard to infection risk, nutritional status, and use in transplant patients.   
 
**SAS and all other SAS Institute Inc. product or service names are registered 
trademarks or trademarks of SAS Institute Inc. in the USA and other countries. ® 
indicates USA registration. 
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Table 1.  Demographic Data 
Characteristic No. (%) 
  n = 62 
Age mean (range, SD), years 60.7 (35-89, 10.8) 
Sex, male 34 (54.8%) 
Affected side, right 56 (90.3%) 
MELD-NA mean (SD) 24 (6.5) 
Etiology of cirrhosis 
Alcohol 20 (32.3%) 
Hepatitis C 18 (29.0%) 
NASH 26 (41.9%) 
Autoimmune 2 (3.2%) 
Alpha-1 Antitrypsin Deficiency 2 (3.2%) 
Other 10 (16.1%) 
Transplant Status, listed* 7 (11.3%) 
Indication for IPC 
Bridge to Transplant 33 (53.2 %) 
Palliative 24 (38.7%) 
Unclear 5 (8.1%) 
* At time of IPC insertion 
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Table 2.  Outcomes of IPC Placement 
Outcome No. (%) 
Complications 22 (35.5%) 
Type of complication 
Empyema 10 (16.1%) 
Skin infection 1 (1.6%) 
Catheter clogged 2 (3.2%) 
Catheter dislodged 6 (9.7%) 
Pneumothorax 2 (3.2%) 
Catheter malfunction 5 (8.1%) 
Other 3 (4.8%) 
Unexpandable lung 3 (4.8%) 
Pleurodesis 9 (14.5%) 
Time to pleurodesis mean (range, SD), days 118 (15-373, 139.6) 
Transplant status after IPC*† 
Listed 19 (57.6%) 
Not listed 14 (42.4%) 
Transplant after IPC† 10 (30.3%) 
Time to transplant mean (range, SD), days 87 (20-175, 49.6) 
Death after placement 48 (77.4%) 
Time to death mean (range, SD), days 180 (0-1258, 284.0) 
Death at 6 months 36 (58%) 
Lost to follow-up 5 (8.1%) 
* Excludes palliative patients 
† Percentages calculated as fraction of transplant-eligible patients 
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Table 3.  Patients with Pleural Infection 
 
      
 
  
Indication PA* Removed Transplant Death† 
LDH, 
Fluid‡ 
(U/L) 
Organism 
Bridge Yes No No Yes 37 Coagulase-negative Staphylococcus 
Palliative No No -- No 162‡ Acinetobacter baumannii, Methicillin-resistant Staphylococcus aureus 
Bridge No Yes Yes No 152‡ No organism identified.   
Bridge No Yes No No 206‡ Coagulase-negative Staphylococcus 
Palliative No No -- Yes N/A Escherichia coli 
Unclear No No -- No 106 Klebsiella pneumoniae, Corynebacterium sp. 
Bridge No Yes Yes No 80‡ Corynebacterium sp., Streptococcus agalactiae 
Bridge No No No Yes 54 Klebsiella pneumonia 
Bridge No No No No 133‡ Coagulase-negative Staphylococcus, Corynebacterium sp., Acinetobacter baumannii, Enterococcus sp. 
Bridge No No No No 57 Klebsiella oxytoca 
* PA = peri-procedural antibiotic 
 
† Death due to infection 
‡
 Exudate per Light’s criteria  
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